MediWound (NASDAQ:MDWD) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD) to a sell rating in a research note released on Thursday.

A number of other research analysts have also recently issued reports on MDWD. Maxim Group increased their target price on shares of MediWound from $25.00 to $30.00 and gave the company a buy rating in a report on Tuesday, July 16th. HC Wainwright reaffirmed a buy rating and issued a $28.00 target price on shares of MediWound in a report on Tuesday, July 16th.

MediWound Stock Down 11.0 %

NASDAQ MDWD opened at $18.60 on Thursday. The stock has a market capitalization of $172.61 million, a P/E ratio of -13.48 and a beta of 0.81. MediWound has a 52-week low of $7.10 and a 52-week high of $24.00. The firm has a 50-day moving average price of $16.93 and a 200 day moving average price of $15.50.

MediWound (NASDAQ:MDWD) last issued its earnings results on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. MediWound had a negative net margin of 64.24% and a negative return on equity of 21.67%. The company had revenue of $4.96 million during the quarter, compared to analysts’ expectations of $4.65 million. On average, equities research analysts expect that MediWound will post -1.93 earnings per share for the current fiscal year.

Institutional Trading of MediWound

Several large investors have recently modified their holdings of MDWD. Janney Montgomery Scott LLC acquired a new stake in shares of MediWound in the first quarter valued at approximately $427,000. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of MediWound in the fourth quarter valued at approximately $803,000. Sargent Investment Group LLC grew its position in shares of MediWound by 7.0% in the fourth quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock valued at $1,111,000 after purchasing an additional 7,125 shares during the last quarter. Yelin Lapidot Holdings Management Ltd. grew its position in shares of MediWound by 45.7% in the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after purchasing an additional 39,348 shares during the last quarter. Finally, Essex Investment Management Co. LLC grew its position in shares of MediWound by 241.6% in the first quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after purchasing an additional 93,705 shares during the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.